Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.00
+0.17 (0.95%)
Nov 24, 2025, 4:00 PM EST - Market closed
Avalo Therapeutics Employees
Avalo Therapeutics had 23 employees as of December 31, 2024. The number of employees increased by 4 or 21.05% compared to the previous year.
Employees
23
Change (1Y)
4
Growth (1Y)
21.05%
Revenue / Employee
$8,348
Profits / Employee
-$4,334,826
Market Cap
326.41M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23 | 4 | 21.05% |
| Dec 31, 2023 | 19 | -1 | -5.00% |
| Dec 31, 2022 | 20 | -24 | -54.55% |
| Dec 31, 2021 | 44 | 13 | 41.94% |
| Dec 31, 2020 | 31 | 13 | 72.22% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AVTX News
- 7 days ago - Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 21 days ago - Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 27 days ago - Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - GlobeNewsWire
- 7 weeks ago - Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources - GlobeNewsWire
- 2 months ago - Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - GlobeNewsWire
- 3 months ago - Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results - Seeking Alpha
- 3 months ago - Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire